New biologic therapy for systemic lupus erythematosus
Authors:
- 1 June 2013
- journal article
- review article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 13 (3) , 405-412
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusionsArthritis & Rheumatism, 2012
- Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysisJournal of Zhejiang University-SCIENCE B, 2012
- Treatment targets in systemic lupus erythematosus: biology and clinical perspectiveArthritis Research & Therapy, 2012
- The Dysregulation of Cytokine Networks in Systemic Lupus ErythematosusJournal of Interferon & Cytokine Research, 2011
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011
- Current and novel therapeutics in the treatment of systemic lupus erythematosusJournal of Allergy and Clinical Immunology, 2011
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2010
- Novel evidence‐based systemic lupus erythematosus responder indexArthritis Care & Research, 2009
- Assessment of disease activity and quality of life in systemic lupus erythematosus – New aspectsBest Practice & Research Clinical Rheumatology, 2009